2020
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism
Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. Journal Of Bone And Mineral Research 2020, 37: 2315-2329. PMID: 36245271, PMCID: PMC10092691, DOI: 10.1002/jbmr.4665.Peer-Reviewed Original ResearchConceptsPrimary hyperparathyroidismFamilial hypocalciuric hypercalcemiaMultiple endocrine neoplasia syndromeCalcium-containing kidney stonesIntestinal calcium hyperabsorptionMore parathyroid glandsParathyroid hormone levelsAsymptomatic primary hyperparathyroidismCalcium-sensing receptorEndocrine neoplasia syndromeNeonatal severe hyperparathyroidismHyperparathyroidism-jaw tumor syndromeJaw tumor syndromeCalcium hyperabsorptionPostmenopausal womenSevere hyperparathyroidismParathyroid hormoneSerum calciumHypocalciuric hypercalcemiaPathophysiologic basisParathyroid cellsParathyroid glandsHormone levelsFiltered loadMetabolic factors
2018
Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia
Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL. Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. Calcified Tissue International 2018, 102: 666-670. PMID: 29383408, PMCID: PMC5957766, DOI: 10.1007/s00223-017-0382-0.Peer-Reviewed Original ResearchConceptsLevels of FGF23Nasal salmon calcitoninSalmon calcitoninStudy drugVisit 2Day 2Levels of PTHPrincipal outcome variableTmP/GFRSingle subcutaneous dosePlacebo nasal sprayNasal calcitoninSerum calciumSubcutaneous doseVisit 4Dihydroxyvitamin DSerum phosphorusVisit 3Final doseVisit 1Nasal sprayClinical trialsSerial measurementsDrug doseFGF23 production
2014
Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study
Carpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D, Gundberg CM, Insogna KL. Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3103-3111. PMID: 25029424, PMCID: PMC4154090, DOI: 10.1210/jc.2014-2017.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkaline PhosphataseBone Density Conservation AgentsChildDouble-Blind MethodErgocalciferolsFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHyperparathyroidismMaleMiddle AgedParathyroid HormonePhosphorusPlacebosProspective StudiesTreatment OutcomeVitamin DYoung AdultConceptsRenal phosphate thresholdGlomerular filtration rateBone scanSerum phosphorusFiltration rateXLH patientsEffect of paricalcitolUse of paricalcitolPlacebo-treated subjectsElevated PTH levelsSerum calcium levelsSuppression of PTHHospital research unitSerum alkaline phosphatase activityPTH levelsCreatinine levelsSecondary outcomesStandard therapyUrinary calciumPlacebo subjectsParathyroid hormoneSerum calciumAlkaline phosphatase activityD levelsSkeletal improvementDenosumab for Treatment of Hypercalcemia of Malignancy
Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for Treatment of Hypercalcemia of Malignancy. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3144-3152. PMID: 24915117, PMCID: PMC4154084, DOI: 10.1210/jc.2014-1001.Peer-Reviewed Original ResearchConceptsHypercalcemia of malignancyProportion of patientsDay 10Serum calciumBone resorptionCommon serious adverse eventsMedian response durationSerious adverse eventsSerum calcium levelsTreatment of hypercalcemiaDuration of responseNew treatment optionsBisphosphonate therapyPrimary endpointSecondary endpointsAdverse eventsBisphosphonate treatmentDurable responsesComplete responseAdvanced cancerTreatment optionsHematologic malignanciesResponse durationDenosumabCalcium levels
2013
Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment
Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. Journal Of The National Cancer Institute 2013, 105: 1417-1420. PMID: 23990665, PMCID: PMC3776443, DOI: 10.1093/jnci/djt225.Peer-Reviewed Original ResearchConceptsHypercalcemia of malignancyBisphosphonate treatmentResponse durationDay 10Albumin-corrected serum calciumTumor-induced bone resorptionIntravenous bisphosphonate treatmentPrespecified interim analysisMedian response durationProportion of patientsKaplan-Meier methodNew treatment optionsDenosumab initiationIntravenous bisphosphonatesSubcutaneous denosumabPrimary endpointRenal failureComplete responseSerum calciumTreatment optionsHCM patientsBone resorptionDenosumabInterim analysisPatientsDenosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).
Hu M, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Wang H, Braun A, Jain R. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM). Journal Of Clinical Oncology 2013, 31: e20512-e20512. DOI: 10.1200/jco.2013.31.15_suppl.e20512.Peer-Reviewed Original ResearchBone resorptionDay 10RANK ligandTumor-induced bone resorptionUnexpected safety findingsSerious adverse eventsNew treatment optionsDenosumab initiationSubcutaneous denosumabPrimary endpointDurable responsesFirst doseMedian durationSafety findingsAdverse eventsComplete responseMedian timeSerum calciumTreatment optionsDenosumabDay 1CSC levelsDlMedianTreatment
2011
Chapter 59 The Hypocalcemic Disorders Differential Diagnosis and Therapeutic Use of Vitamin D
Carpenter T, Insogna K. Chapter 59 The Hypocalcemic Disorders Differential Diagnosis and Therapeutic Use of Vitamin D. 2011, 1091-1106. DOI: 10.1016/b978-0-12-381978-9.10059-9.ChaptersTotal serum calcium concentrationCalcium concentrationSerum calcium concentrationTotal serum calciumDL declineSecondary hyperparathyroidismSerum calciumSkeletal consequencesVitamin DCalcium measuresClinical guidelinesDifferential diagnosisMineralization defectNormal individualsTherapeutic useHypocalcemiaSerum albuminExtracellular fluidCalcium deficiencyDlCalciumAlbuminHyperparathyroidismHypokalemiaHypoparathyroidism
2002
Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-2898. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.Peer-Reviewed Original ResearchConceptsEstrogen-deficient womenIL-6/ILSkeletal sensitivityIL-6IL-6sREstrogen deficiencyCytokine systemIL-6 soluble receptorUrine N-telopeptideAction of PTHPrevious animal studiesNTx excretionPTH infusionPostmenopausal womenSerum calciumN-telopeptideCytokine productionTNF-alphaExaggerated increaseIL-1betaHormonal statusBaseline valuesSoluble receptorAnimal studiesColony-stimulating factor-1
1996
Effects of continuous glucocorticoid infusion on bone metabolism in the rat
King CS, Weir EC, Gundberg CW, Fox J, Insogna KL. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcified Tissue International 1996, 59: 184-191. PMID: 8694896, DOI: 10.1007/s002239900107.Peer-Reviewed Original ResearchConceptsDEX treatmentBone metabolismUrinary calcium/creatinine ratioCalcium/creatinine ratioIntact parathyroid functionLevels of PTHSprague-Dawley ratsTartrate-resistant acid phosphataseParathyroid functionTime-dependent mannerCreatinine ratioSerum calciumBone turnoverContinuous administrationParathyroidectomized animalsSerum concentrationsSupraphysiologic dosesGlucocorticoid infusionDawley ratsFemoral weightHistomorphometric findingsBone massPTX animalsBone volumeDexamethasone
1992
Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo
Weir E, Terwilliger G, Sartori L, Insogna K. Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo. Calcified Tissue International 1992, 51: 30-34. PMID: 1393774, DOI: 10.1007/bf00296214.Peer-Reviewed Original ResearchConceptsBovine parathyroid hormoneSerum calciumParathyroid hormone-like proteinDaily subcutaneous injectionsPotent bone-resorbing agentHormone-related proteinDose-dependent increaseDry bone weightHighest dose levelHormone-like proteinBone-resorbing agentsBone dry weightLow dosage levelsHumoral hypercalcemiaParathyroid hormoneDihydroxyvitamin DMale SpragueDawley ratsSubcutaneous injectionHuman PTHrPBone calciumAnabolic agentsPTHrP actionDose levelsHigh doses
1990
Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase
Brown G, Morris C, Mitnick M, Insogna K. Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase. Journal Of Bone And Mineral Research 1990, 5: 1037-1041. PMID: 1964358, DOI: 10.1002/jbmr.5650051007.Peer-Reviewed Original ResearchConceptsSerum calciumBone resorptionHumoral hypercalcemiaCarbonic anhydrase inhibitorsNephrogenous cyclic AMP excretionCyclic AMP excretionMean serum calciumOsteoclastic bone resorptionDrug-treated animalsLeydig cell tumorMechanism of actionUrine phosphorusUrine calciumSerum phosphorusCell tumorsAcetazolamide treatmentHypercalcemiaSignificant fallFisher ratsObserved hypercalcemiaResorptionDirect inhibitionSignificant riseMalignancyRats
1989
Synthesis of a Gene Encoding Parathyroid Hormone-Like Protein-(1–141): Purification and Biological Characterization of the Expressed Protein*
THORIKAY M, KRAMER S, REYNOLDS F, SORVILLO J, DOESCHER L, WU T, MORRIS C, BURTIS W, INSOGNA K, VALENZUELA D, STEWART A. Synthesis of a Gene Encoding Parathyroid Hormone-Like Protein-(1–141): Purification and Biological Characterization of the Expressed Protein*. Endocrinology 1989, 124: 111-118. PMID: 2535801, DOI: 10.1210/endo-124-1-111.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBase SequenceBiological AssayBone and BonesCalciumCloning, MolecularCyclic AMPDNADogsEscherichia coliGenes, SyntheticKidneyMolecular Sequence DataMolecular WeightNeoplasm ProteinsOsteosarcomaParathyroid HormoneParathyroid Hormone-Related ProteinPeptide FragmentsPlasmidsRatsRecombinant ProteinsTumor Cells, Cultured
1988
Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats.
Stewart AF, Mangin M, Wu T, Goumas D, Insogna KL, Burtis WJ, Broadus AE. Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcemia in rats. Journal Of Clinical Investigation 1988, 81: 596-600. PMID: 3339131, PMCID: PMC329608, DOI: 10.1172/jci113358.Peer-Reviewed Original ResearchConceptsBone-resorbing agentsMicrograms/hParathyroid hormone-like proteinFetal rat long bonesAdenylate cyclasePotent bone-resorbing agentHormone-like proteinRat long bonesMembrane adenylate cyclaseSerum calciumHumoral hypercalcemiaOsmotic minipumpsBone resorptionPotent agonistLong bonesSuch synthetic peptidesHypercalcemiaRatsDlVivo bioactivityCyclaseSynthetic peptidesAgentsMinipumpsPatients
1985
Elevations in Circulating 1,25-Dihydroxyvitamin D in Three Patients with Lymphoma-Associated Hypercalcemia*
ROSENTHAL N, INSOGNA K, GODSALL J, GAC A, SMALDONE L, WALDRON J, STEWART A. Elevations in Circulating 1,25-Dihydroxyvitamin D in Three Patients with Lymphoma-Associated Hypercalcemia*. The Journal Of Clinical Endocrinology & Metabolism 1985, 60: 29-33. PMID: 3871092, DOI: 10.1210/jcem-60-1-29.Peer-Reviewed Original ResearchConceptsDihydroxyvitamin DBone marrow biopsyElevated plasma levelsImmunoreactive PTH levelsUrinary cAMP excretionVitamin D metabolitesAdenylate cyclase-stimulating activityCyclase-stimulating activityPTH levelsRadionuclide scansMedical therapyMalignant lymphomaSerum calciumSurgical excisionMarrow biopsyCertain patientsRapid normalizationSplenic lymphomaSystemic mediatorsUrinary excretionD metabolitesPlasma levelsCAMP excretionTumor extractsPatients
1982
Influence of pregnancy on immunoreactive parathyroid hormone levels
Gillette M, Insogna K, Lewis A, Baran D. Influence of pregnancy on immunoreactive parathyroid hormone levels. Calcified Tissue International 1982, 34: 9-12. PMID: 6279256, DOI: 10.1007/bf02411200.Peer-Reviewed Original ResearchConceptsImmunoreactive PTHTubular maximum phosphate reabsorptionImmunoreactive parathyroid hormone levelsAge-matched female controlsHealthy pregnant patientsNephrogenous cAMP excretionParathyroid hormone metabolismHealthy age-matched female controlsParathyroid hormone levelsInfluence of pregnancySignificant increaseBiological effectsIPTH levelsPregnant patientsCreatinine clearanceUrinary calciumCreatinine ratioPTH metabolismSerum calciumSerum phosphorusThird trimesterVitamin DBlood levelsBone resorptionPhosphate reabsorption